MiNK Therapeutics (INKT) Stock Price, News & Analysis

Company Overview

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. The company’s research centers on invariant natural killer T (iNKT) cells, an immune cell type that can recognize and attack tumor cells while helping activate broader immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed for use as an off-the-shelf treatment. The candidate has been evaluated in clinical studies involving patients with advanced cancers, including solid tumors and hematologic malignancies, both as a standalone therapy and in combination with other cancer treatments.

The company is also advancing its broader iNKT cell therapy platform and additional product candidates intended to address challenges such as tumor immunosuppression and limited immune-cell activity within solid tumors. MiNK Therapeutics was established to translate iNKT-cell research into cancer treatments and conducts its development activities through clinical and research programs in the United States and through collaborations where applicable.

Key Stats

• Today's Range: $10.12 to $10.65
• 50-Day Range: $10.53 to $12.73
• 52-Week Range: $8.48 to $16.93
• Volume: 7,172 shs
• Average Volume: 109,585 shs
• Market Capitalization: $52.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Hold

MiNK Therapeutics Stock Analysis - MarketRank™

MiNK Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 400th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

MiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

MiNK Therapeutics has a consensus price target of $35.00, representing about 242.1% upside from its current price of $10.23.

Amount of Analyst Coverage

MiNK Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MiNK Therapeutics are expected to decrease in the coming year, from ($1.93) to ($1.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MiNK Therapeutics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MiNK Therapeutics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.22% of the float of MiNK Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

MiNK Therapeutics has a short interest ratio ("days to cover") of 3.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MiNK Therapeutics has recently decreased by 13.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MiNK Therapeutics does not currently pay a dividend.

Dividend Growth

MiNK Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

MiNK Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.40% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.87% of the stock of MiNK Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INKT
• CIK: 1840229
• Web: www.minktherapeutics.com
• Phone: 212-994-8250
• Fax: N/A
• Employees: 15
• Year Founded: 2017

Price Target and Rating

• Average Price Target for MiNK Therapeutics: $35.00
• High Price Target: $35.00
• Low Price Target: $35.00
• Potential Upside/Downside: +242.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -92.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.03) per share
• Price / Book: -3.38

Miscellaneous

• Outstanding Shares: 5,103,000
• Free Float: 4,062,000
• Market Cap: $52.20 million
• Optionable: No Data
• Beta: 0.47